Remarkably, administration of JTE-013, a Sphingosine-1-phosphate receptor 2 (S1PR2) antagonist, in a mouse model of OVA-induced chronic airway inflammation and remodeling, decreased inflammatory cell recruitment and mucus production, reduced BAL IL-1, IL-4, IL-5, and serum IgE levels and attenuated collagen deposition and smooth muscle cell-activating proteins in the lungs. The gene discussed is S1PR2; the disease is inflammation.